ReviewNeuro-oncology practice2025

Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma.

Patrick Roth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.